Denali Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

Denali Therapeutics

01/05/2023 12:11

* Denali Therapeutics Inc  DNLI.OQ   DNLI.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 3
(estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 31.8% decrease in revenue to $28.719 million from
$42.14 million a year ago, according to the mean estimate from
12 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Denali Therapeutics
Inc
is for a loss of 70 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Denali
Therapeutics Inc is $52​, above​ its last closing price
of $24.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.77       -0.79      -0.75     Beat    5.1
 Sep. 30 2022  -0.78       -0.81      -0.84     Missed  -4.2
 Jun. 30 2022  -0.53       -0.55      -0.48     Beat    12.6​
 Mar. 31 2022  -0.51       -0.51      -0.53     Missed  -4.3
 ​​Dec.        -0.43       -0.41      -0.62     Missed  -49.8
 31 2021                                                
 Sep. 30 2021  -0.52       -0.47      -0.69     Missed  -45.6​
 Jun. 30 2021  -0.46       -0.41      -0.50     Missed  -22.2
 Mar. 31 2021  -0.33       -0.34      -0.58     Missed  -68.4
 This summary was machine generated May 1 at 11:11 GMT.  All
figures in US dollars  unless otherwise stated